GCM
BBH icon

Gables Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Gables Capital Management’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-150
Closed -$17K – 345
2018
Q4 		$17K Hold
150
– – 0.01% 242
2018
Q3 		$20K Hold
150
– – 0.02% 242
2018
Q2 		$18K Buy
+150
New +$17.7K 0.01% 252

Other funds holding BBH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MJRIC
Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Gables Capital Management's BBH Position: Q1 2019 in Review

Gables Capital Management sold out of VanEck Biotech ETF (BBH) in Q1 2019, closing a stake of 150 shares — an estimated $17K sold.

Gables Capital Management first reported a position in BBH in Q2 2018 and held it in 3 quarters. The position peaked at $20K in Q3 2018. 90 funds tracked by Wall St. Rank hold BBH as of Q1 2019.

  • Gables Capital Management reported no remaining VanEck Biotech ETF position as of Q1 2019 after selling out during the quarter.
  • Gables Capital Management sold 150 VanEck Biotech ETF shares in Q1 2019, an estimated $17K.
  • Gables Capital Management first reported a position in VanEck Biotech ETF in Q2 2018 and held it in 3 quarters.
  • Gables Capital Management's VanEck Biotech ETF position peaked at $20K in Q3 2018.
  • 90 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2019.

Based on Gables Capital Management's 13F filing for Q1 2019, filed 30 Apr 2019.